Arrowhead Pharmaceuticals, Inc.
NEWS
For the first time in two years, the European Association for the Study of the Liver’s International Liver Congress was back on-site with cutting-edge research in hepatology and other sectors.
Four biotech companies are holding Research-and-Development Day events to present and discuss their pipelines. Here’s a look.
A roundup of last week’s top clinical trial updates and news.
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.
ARO-HSD will be evaluated in a Phase I/II trial that will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of its ability to target HSD17B13 as a treatment for NASH.
Arrowhead will conduct its activities through preclinical development stages, while Horizon will have sole responsibility for the clinical development and commercialization of the medicine.
The investigational drug, ARO-AAT, is a potential first-in-class treatment that reduces the generation of mutant alpha-1 antitrypsin protein (Z-AAT), the primary contributor to liver disease progression in patients with AATLD.
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
Christopher Anzalone, Arrowhead’s chief executive officer, took time to speak with BioSpace about the company’s large pipeline and why they’re so excited about 2020.
JOBS
IN THE PRESS